Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic, Inc. (Nasdaq: HOLX) generates a steady flow of news centered on women’s health, medical technology innovation and corporate developments. As a company that describes itself as focused on developing technologies to detect, diagnose and treat health conditions, many of its announcements highlight advances in diagnostics, breast imaging, oncology testing and digital pathology.
Investors and healthcare professionals following HOLX news will find updates on Hologic’s diagnostic platforms, such as the Panther and Panther Fusion systems, including regulatory milestones like FDA clearance and CE marking for new assays. Recent communications have covered automated molecular tests for gastrointestinal bacterial pathogens, which expand the company’s infectious disease testing menu and illustrate its emphasis on rapid, molecular-based diagnostics.
Hologic’s news feed also features developments in breast health technologies. The company has publicized data on its AI-powered mammography tools, such as the Genius AI Detection solution and 3DQuorum imaging technology, through studies conducted at major medical centers and presented in peer-reviewed journals or at scientific meetings. These stories often focus on how artificial intelligence can support radiologists by flagging suspicious areas on mammograms and streamlining image review without compromising cancer detection performance.
Oncology and precision medicine are recurring themes. Hologic and its subsidiary Biotheranostics, Inc. issue updates about the Breast Cancer Index Test, including new clinical evidence presented at conferences like the San Antonio Breast Cancer Symposium. These releases describe how the test may inform extended endocrine therapy decisions for patients with early-stage, hormone receptor–positive breast cancer and examine its performance in various patient subgroups.
Beyond technology and clinical data, Hologic’s news includes educational initiatives and partnerships, such as the "Ultimate Defense" cervical cancer screening awareness campaign with professional basketball player Erica Wheeler, and collaborations in epigenomics and pharmaco-epigenetics through Hologic Diagenode and co-marketing agreements. Corporate and financial announcements, including quarterly earnings releases and the proposed acquisition of Hologic by funds managed by Blackstone and TPG, provide additional context for HOLX stockholders.
For readers interested in HOLX news, this page offers a centralized view of Hologic’s product milestones, clinical research, public health campaigns and transaction-related updates, making it a useful resource for tracking how the company’s activities evolve over time.
Hologic (Nasdaq: HOLX) has been acquired by funds managed by Blackstone and TPG for up to $79 per share, making Hologic a private company. Stockholders receive $76 cash plus a non-tradable CVR of up to $3 tied to Breast Health revenue goals.
Deal announced Oct 21, 2025, approved Feb 5, 2026. José (Joe) E. Almeida is named CEO; Hologic common stock has ceased trading and will be delisted. Minority investors include ADIA and an affiliate of GIC.
Broadstone Net Lease (NYSE: BNL) will be added to the S&P SmallCap 600 effective prior to the opening of trading on April 9, 2026, replacing DigitalOcean Holdings (DOCN). The change is part of concurrent index rebalances that move Casey's General Stores (CASY) into the S&P 500 and DOCN into the S&P MidCap 400.
The table of changes lists each addition and deletion by index and sector on the effective date.
Hologic (Nasdaq: HOLX) announced that CEO Steve MacMillan will retire when the company’s go-private transaction with Blackstone and TPG closes, with regulatory approvals complete and closing expected on or about April 7, 2026.
Over MacMillan’s 12+ years, Hologic reported revenue +65%, non-GAAP EPS +184%, share price +241%, and added >1,500 employees. The next CEO will be named at closing.
Hologic (Nasdaq: HOLX) released the fifth edition of the Global Women’s Health Index on March 17, 2026, showing persistent global screening gaps: an estimated 1.5 billion women were not tested for cancer, high blood pressure, diabetes or STIs in the past year.
Year 5 reports: 13% tested for any cancer, 39% for high blood pressure, 24% for diabetes and 10% for STIs; the world Index score remains 54 (no change since Year 1).
Hologic (Nasdaq: HOLX) announced FDA approval of the Aptima® HPV Assay for clinician-collected HPV primary screening on February 4, 2026. The Aptima test is the only FDA-approved mRNA-based HPV assay and is effective for detecting CIN2+ and CIN3+.
The approval follows a real-world study of over 650,000 women comparing Aptima to an FDA-approved DNA HPV test, which found the Aptima assay had clinically comparable sensitivity. Hologic now offers co-testing, Pap testing, and HPV primary testing as FDA-approved screening options.
Hologic (NASDAQ: HOLX) reported Q1 FY2026 revenue of $1,047.8 million, up 2.5% (1.3% constant currency). GAAP diluted EPS was $0.79 (down 9.2%) and non-GAAP diluted EPS was $1.04 (up 1.0%). Cash flow from operations grew 21.4% to $229.9 million. The company set a Feb 5, 2026 special meeting to vote on the proposed merger with funds managed by Blackstone and TPG.
Hologic (Nasdaq: HOLX) will release financial results for the first quarter of fiscal 2026 on Thursday, January 29, 2026 after the market closes. The company said it will not host a quarterly conference call or provide financial guidance due to its pending acquisition by Blackstone and TPG. The announcement directs investors to the company website for more information.
Hologic (Nasdaq: HOLX) launched Ultimate Defense, a U.S. educational campaign with professional basketball player Erica Wheeler to raise awareness of routine cervical cancer screening and encourage conversations with healthcare providers.
The campaign debuts during Cervical Health Awareness Month (January 2026) with a public service announcement and social content urging Pap and HPV co-testing per U.S. guidelines for ages 21–65 and directing people to YourUltimateDefense.com for resources.
Hologic (Nasdaq: HOLX) reported a retrospective study of 7,500 digital breast tomosynthesis screening exams (2016–2019) using Genius AI Detection 2.0 that examined false-negative and cancer cases.
The AI flagged approximately 32% of 100 false-negative exams and correctly localized suspicious areas; it also flagged almost 90% of 500 radiologist-identified cancer cases and localized their locations. The algorithm more often flagged invasive ductal and lymph node–positive cancers and less often flagged invasive lobular and grade I cancers.
Study limits include a single academic center, a predominantly Caucasian population, small subgroup sizes, and no evaluation of patient outcomes or real-world workflow integration.
Hologic (Nasdaq: HOLX) announced 11 studies featuring the Breast Cancer Index (BCI) Test to be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) on December 10–11, 2025. The data explore expanded utility in premenopausal women, comparative analyses versus the 21-gene assay, and consistency across sample types.
Key highlights include a translational analysis of the SOFT and TEXT trials suggesting BCI may identify premenopausal patients at minimal distant-recurrence risk and a registry analysis showing BCI can re-stratify 21-gene assay risk groups. The company cites >9,000 providers using BCI and multiple real-world and independent studies supporting clinical decision-making for extended endocrine therapy.